Kura Oncology
KURA
171 hedge funds and large institutions have $1.94B invested in Kura Oncology in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 70 increasing their positions, 55 reducing their positions, and 37 closing their positions.
3,713% more call options, than puts
Call options by funds: $17M | Put options by funds: $446K
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
27% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 55
3.23% more ownership
Funds ownership: 100.36% → 103.59% (+3.2%)
9% less capital invested
Capital invested by funds: $2.12B → $1.94B (-$183M)
14% less funds holding
Funds holding: 198 → 171 (-27)
68% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$60.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$44.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$44.7M |
| 4 |
Holocene Advisors
New York
|
+$19.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$51.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$21.2M |
| 3 |
RI
RTW Investments
New York
|
-$19.6M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$19M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$14M |
KURA Hedge Fund Activity: Q1 2021 in Review
171 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2021, worth a combined $1.94B — down 8.6% from $2.12B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of KURA and 12 opened new positions — a net loss of 25 holders — while 55 trimmed existing stakes and 70 added.
The largest buyer was EcoR1 Capital, adding an estimated $60.7M. The largest seller was Citadel Advisors, cutting an estimated $51.6M.
- 171 institutional investors held Kura Oncology (KURA) as of Q1 2021, down from 198 in Q4 2020.
- Funds reported $1.94B of Kura Oncology stock for Q1 2021, down 8.6% quarter-over-quarter.
- 12 funds opened new Kura Oncology positions in Q1 2021 and 37 closed out, a net change of -25 holders.
- The largest Kura Oncology buyer in Q1 2021 was EcoR1 Capital, an estimated $60.7M added.
- The largest Kura Oncology seller in Q1 2021 was Citadel Advisors, an estimated $51.6M sold.
Based on aggregated 13F filings for Q1 2021.